



FOR IMMEDIATE RELEASE

**BAXTER ANNOUNCES LAUNCH OF BAXJECT® II HI-FLOW
NEEDLELESS TRANSFER DEVICE FOR *FEIBA®/VH* Therapy**

New Enhancement Now Available in Canada

MISSISSAUGA, ON, May 10, 2010: Baxter Corporation today announced the launch of BAXJECT II Hi-Flow, a needleless transfer device designed to make the reconstitution of FEIBA [Anti-inhibitor Coagulant Complex] bypassing therapy easier, faster and safer than needles alone. BAXJECT II Hi-Flow represents the latest enhancement for reconstitution of FEIBAVH therapy, an integral part of inhibitor management for people with hemophilia.

"The new mixing device for FEIBA offers patients a safe, needleless way to mix the product more efficiently", said Georgina Floros, Hemophilia Nurse Coordinator with St. Michael's Hospital (Toronto, Ontario).

"Given the novel design of BAXJECT II Hi-Flow and the sustained activity of FEIBA that provides a 6 to 12 hour dosing interval, inhibitor patients may now spend less time preparing their FEIBA therapy and focus on their life's activities between infusions," says Dr. Adel Gehchan, Director of Clinical and Medical Affairs, Baxter Corporation.

BAXJECT II Hi-Flow is provided as a complete single package containing a vial of FEIBA therapy, which is in a powder form, and a vial of sterile water. The BAXJECT II Hi-Flow design makes mixing easier by avoiding the need for valve turning and air injection. The design also provides a straightforward color-coding system that makes reconstitution intuitive. FEIBA therapy mixing time is reduced as a result of fewer mixing steps and shorter preparation time. Safety is supported by the inclusion of a built-in filter to maintain product purity, and a reduced risk of accidental needle-stick injury because the needleless design contains no glass parts or syringes.

About FEIBA

FEIBA is indicated for the control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and hemophilia B patients with inhibitors. As a bypassing

therapy, FEIBA is used to “bypass” the normal coagulation cascade to prevent and/or stop bleeding in inhibitor patients.

Baxter Research and Development

Baxter focuses its scientific resources and leverages strategic collaborations to advance the treatment of hemophilia and blood clotting disorders. Building on its history of innovation, the company is developing therapies to provide less invasive dosing techniques, require less frequent infusions, and/or reduce the potential for inhibitor formation to improve the lives of people with bleeding disorders.

About Baxter

As a subsidiary of Baxter International Inc., Baxter Corporation (Canada) manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. More information:

www.baxter.ca.

###

Media Contacts:

Lan Lai-Minh

(905) 281-6454

lan_lai_minh@baxter.com